Mother Nature Makes
The Best Medicines!
Lypo-Spheric GSH
for Parkinson's Disease
1-800-952-5884
As of 2009, there are about 1 million people suffering from Parkinson’s Disease (PD), and 50,000 new cases are diagnosed each year. One of the strongest links to PD is exposure to pesticides and herbicides, especially paraquat, pyridaben, fenazaquin, dieldrin and rotenone. Repeated exposures to “small” amounts of these pesticides, none of which would be capable of causing PD by itself, results in cumulative damage to the nerve cells involved in PD. In other words, there is a synergism caused by being exposed to small amounts of 2 or more of these neurotoxic chemicals repeatedly. Heavy metals (i.e. mercury, lead, etc.) can also damage nerve cells involved in PD. People with heavy metals in their bodies that are then exposed to pesticides are even more at risk of developing PD.
One of the consistent findings in PD is that those who develop the disease have very low levels of glutathione in their cells. Reduced L-glutathione, most commonly called GSH, is the most powerful naturally occurring antioxidant in all human cells. GSH is a tripeptide composed of the amino acids glutamic acid, cysteine and glycine. GSH is found in high concentrations in the mitochondria of nerve cells. Mitochondria are the energy factories inside cells. When mitochondria are working properly everything is fine. When mitochondria are poisoned by heavy metals/pesticides, they begin to produce large amounts of free radicals instead of energy. These free radicals destroy nerve cells from within. Glutathione quenches these free radicals. As glutathione is used up, the risk of nerve cell death and PD increases. Studies have shown that not only are glutathione levels lower in people that have PD, but the levels of glutathione fall as the disease progresses.
Can someone with PD take GSH to help replenish the low levels of GSH in their nerve cells? Supplementing GSH in tablets or capsules is not effective because stomach acid and digestive enzymes will break down GSH before it can be absorbed. Thanks to a new technology called Liposomal Encapsulation Technology (LET), there is now a way to protect GSH from stomach acid and digestive enzymes. This product is called Lypo-Spheric GSH.
What is Liposomal Encapsulation Technology (LET)? A liposome is a small sphere made of a lipid coating. The GSH is located inside (encapsulated) these small spheres where it is protected from stomach acid and digestive enzymes. Lypo- Spheric GSH allows glutathione to be absorbed intact so that it can get to the bloodstream and travel throughout the body. Once Lypo- Spheric GSH reaches the brain it releases GSH to nerve cells. Once inside nerve cells, glutathione quenches the free radicals that are destroying these cells.
There is no better way to supplement glutathione than Lypo- Spheric GSH. There are 30 packets of Lypo-Spheric GSH per box. Each packet contains 450 mg of reduced glutathione (GSH). We recommend that individuals with PD take a minimum of 2 packets of Lypo-Spheric GSH per day, one in the morning before breakfast and one in the evening before bed. Snip or tear the notched end of the packet, squeeze into your favorite cool beverage and drink on an empty stomach. Do not mix with a hot beverage or with any high-speed blender or food processeor.
One box of Lypo-Spheric GSH costs $69.95. We offer FREE shipping on this product for customers in the USA.
Ingredients: Reduced glutathione (450 milligrams) and vitamin B12 (10 micrograms) in an essential phospholipid liposome (1000 milligrams).
Purchase Lypo-Spheric GSH via our SECURE Order Form!
Research Articles on Glutathione and Parkinson's Disease
Di Monte DA; Chan P; Sandy MS, Glutathione in Parkinson’s disease: A link between oxidative stress and mitochondrial damage? Ann Neurol. 1992 Suppl (32); S111-5.
Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK. Glutathione Depletion Leads to Symptoms of Parkinson's Disease in Mice. J Neurosci. 2007 Dec 19;27(51):13997-4006.
Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD, Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol, 36(3); 348-55 1994 Sep.
Merad-Boudia M; Santiard-Baron D; Saill’e C; Ceballos-Picot I, Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: Relevance to Parkinson’s disease. Biochem Pharmacol, 56(5):645-55 1998 Sep 1.
Perry TL; Yong V, Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in substantia nigra of patients. Neurosci Lett 1986; 67:269-74.
Riederer P; Sofic E; Rausch W; Schmidt B; Reynolds G; Jellinger K; Youdim M, Transition metals, ferrentin, glutathione, and ascorbic acid in pakinsonian brains. J Neurochem 1989; 52:515-520.
Pearce R; Owen S; Daniel S; Jenner P; Marsden C, Alterations in the distribution of glutathione in substantia nigra in Parkinson's disease. J Neural Transm 1997; 104:661-77.
Jenner P; Dexter D; Sian J; Schapira A; Marsden C; Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease. Ann Neurol 1992; 32:S82-S87.
Perry TL; Godin D V; Hansen S; Jones K, Parkinson's Disease: a disorder due to nigral cell glutathione deficiency. Neurosci Lett 1982; 33:300-10.
Jha N; Jurma O; Lalli G; Liu X; Pettus EH, et al, Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity. J Biol Chem. 2000 Aug; Vol 275(34): 26096-101.
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P and Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994 Sep;36(3):348-55.
Jenner P, Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl. 1993;146:6-13.
S. Canals, M. J. Casarejos, S. de Bernardo, E. RodrõÂguez-MartõÂn and M. A. Mena, Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J Neurochem. (2001) 79, 1183-1195.
Jenner P, What process causes nigral cell death in Parkinson's disease? Neurol Clin. 1992 May 10(2):387-403.
Kidd P, Parkinson’s Disease as Multifactorial Oxidative Neurodegeneration: Implications for Integrative Management. Altern Med Rev 2000;5(6):502-545.
Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, Andersen JK, Inducible Alterations of Glutathione Levels in Adult Dopaminergic Midbrain Neurons Result in Nigrostriatal Degeneration. Journal of Neuroscience, December 19,2007. 27(51):13997–14006.
Return to Nature Doc's On-Line Catalog.
DISCLAIMER: The information and products on this web page have not been evaluated by the Food and Drug Administration nor are they intended to diagnose, treat, cure or prevent any disease.
© 1997-2012 Nature Doc. All Rights Reserved.
P.O. Box 777 Joshua, TX 76058-0777 USA
1-800-952-5884 or 817-607-8531
info@naturedoc.com